James E. Krause
Keine laufenden Positionen mehr
Profil
James E.
Krause worked as the Director-Medical Scientist Training Program at Washington University in St. Louis from 1984 to 1997.
He then worked as the Senior Vice President-Biology at Neurogen Corp.
and as the Executive Vice President-Research & Development at ARMGO Pharma, Inc. Krause received his undergraduate and doctorate degrees from the University of Wisconsin.
Ehemalige bekannte Positionen von James E. Krause
| Unternehmen | Position | Ende |
|---|---|---|
| Washington University in St. Louis | Corporate Officer/Principal | 01.01.1997 |
ARMGO Pharma, Inc.
 ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | - |
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Corporate Officer/Principal | - |
Ausbildung von James E. Krause
| University of Wisconsin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Neurogen Corp.
Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
ARMGO Pharma, Inc.
ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Health Technology |
